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Abstract
Background: Effective bile duct drainage is crucial to the health-related quality of life of patients with
jaundice caused by obstruction of the bile duct by inoperable malignant tumours.
Methods: All patients who were treated at Uppsala University Hospital, Sweden with percutaneous
stenting between 2000 and 2005 were identified retrospectively. Data on the location of the obstruction
and type of stent used, date and cause of death and date of stent failure were abstracted from the
patients' notes. Stent patency was defined as the duration from the insertion of the stent to the date of
failure. In cases in which the cause of death was directly related to failure of the stent, the date of death
was defined as the patency endpoint.
Results: A total of 64 patients (34 women, 30 men) were identified. Their mean age was 71 years
(standard deviation 11 years). The median length of patency was 11.4 months. Stent diameter >10 mm
and distal stricture were found to be associated with significantly longer patency time in univariate Cox
proportional hazard analysis. In multivariate Cox proportional hazard analysis, only location of the stricture
was found to be independently and significantly associated with patency time.
Discussion: Percutaneous stenting is a good alternative for patients with obstructive jaundice and a life
expectancy 1 year. It may give instant relief from the symptoms associated with jaundice. Patency time
may be prolonged by using stents with a diameter 10 mm. However, patency time was found to be
lower for hilar tumours.
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Introduction
The majority of malignant tumours that cause bile duct obstruc-
tion, particularly pancreatic cancer, papillary cancer, biliary duct
cancer or gall bladder cancer, are inoperable at the time of diag-
nosis.1,2 Furthermore, as these tumours usually occur in the
elderly population, the advanced surgery required for radical
management is often futile. The main objective for these patients
is to improve their health-related quality of life. The factor that
most greatly limits quality of life, especially early on, is the devel-
opment of obstructive jaundice. Effective drainage of bile is
therefore crucial. This may be achieved through percutaneous
transhepatic biliary drainage (PTBD),3 endoscopic stenting,4 sur-
gical bilioenteric bypass 5 or percutaneous transhepatic biliary
stenting.6–8 Percutaneously inserted transhepatic biliary self-
expanding metal stents (SEMS) may provide effective drainage of
the bile ducts and relief of jaundice, without the problems and
daily dressing requirements associated with PTBD, and catheter
changes can be planned or performed as required. In most cases,
PTBD is associated with a much lower morbidity than surgical
bilioenteric bypass and may be more easily achieved than endo-
scopic stenting, especially in patients with obstructions close to or
above the bile duct bifurcation.9 However, remaining life expect-
ancy must be taken into account when deciding on percutaneous
transhepatic biliary stenting because these stents inevitably cease
to function at some stage as a result of tumour overgrowth or
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because the stent becomes clogged or fractured. If the subject’s life
expectancy is considerably longer than the expected patency time
of the stent, repeated measures to drain the bile may be required.
This may cause the patient unnecessary episodes of jaundice or
cholangitis, so reliable knowledge of stent patency and factors
associated with stent failure are therefore of great importance. The
way in which the SEMS is inserted and how it is located in relation
to the stricture are considered crucial to successful drainage
because a major cause of stent failure is tumour overgrowth.7
The aims of the present study were to assess the patency of
SEMS inserted via a percutaneous transhepatic biliary approach
and to explore factors predicting patency, especially with regard to
the type of SEMS and its location.
Materials and methods
All patients who were treated at Uppsala University Hospital with
percutaneous transhepatic biliary stenting for malignant bile duct
obstruction during the period 2000–2005 were identified retro-
spectively. A total of 64 patients, including 34 women and 30 men,
were identified. Their mean age was 71 years (standard deviation
11 years). Data on the location of the obstruction and type of stent
used, date and cause of death and, if applicable, date of stent
failure, were abstracted from the patients’ notes. Stent failure was
defined as persistent or recurrent jaundice. Proximal direction was
defined as towards the liver and distal as towards the intestine.
All patients received PTBD for initial drainage. After an initial
period of 2–6 weeks, the PTBD was changed to an SEMS. Inser-
tion of the stent was performed under fluoroscopy over a
guidewire through an 8-Fr, 30-cm-long introducer (William Cook
Europe Aps, Bjaeverskov, Denmark) after the PTBD had been
removed. All stents were allowed to pass through the papilla of
Vater about 1–2 cm into the duodenum. The length of the stent
was chosen according to the length of the stricture so that the stent
extended 2 cm beyond the tumour margin. The stent was
dilated if it was compressed by the tumour, usually with an 8-mm
balloon catheter. Function was checked by injecting contrast and
observing its passage through the stent. If the passage of contrast
into the duodenum showed no sign of obstruction, the guidewire
and introducer were removed. If not, a temporary drainage cath-
eter was left in place and tested after a few days and then removed
if the passage of contrast was satisfactory. The stents used were the
Wallstent™ (Boston Scientific Corp., Natick, MA, USA), the ZA™
(Cook Medial, Möenchengladbach, Germany), the Luminexx™
(Bard, Karlsruhe, Germany), and the Sinus Flex™ (Optimed
GmbH, Ettlingen, Germany). Six patients with hilar tumours
received double Luminexx™ stents. The median length of the
stents was 80 mm (range 60–100 mm). The median diameter was
10 mm (range 6–12 mm).
Patency was followed until the patient developed signs of stent
failure (i.e. jaundice or cholangitis). If the patient developed clini-
cal signs of stent failure, he or she was evaluated using non-
invasive imaging techniques, usually computed tomography or
ultrasound. In most cases, efforts were made to re-establish stent
function after occlusion, usually through a new percutaneous pro-
cedure. Only patency until first failure is considered in this report;
patency after re-intervention is not included in the analysis.
All procedures were carried out in accordance with the Helsinki
Declaration of 1983.
Statistics
Stent patency was defined as the duration from the insertion of
the stent until the date of failure. If the cause of death was directly
related to stent failure, the date of death was defined as the patency
endpoint. If no stent failure occurred, stent patency was consid-
ered as censored at the date of death or at the end of the study
period (17 March 2006). Age, gender, type of stricture and size and
location of the stent were included as covariates in univariate and
multivariate Cox proportional hazard analysis, with patency as
outcome measure. The multivariate model was constructed by
stepwise selection of the covariates, with entry testing based on the
significance of the score statistic, and removal testing based on the
probability of a likelihood ratio statistic based on the maximum
partial likelihood estimates.
Results
Diagnoses and stricture levels are presented in Table 1. Fourteen
patients had strictures at the biliary bifurcation. The strictures
were characterized according to the Bismuth–Corlette classifica-
tion10 as hilar type 1 (n = 2) and hilar type 4 (n = 12). The
Table 1 Diagnoses and stricture levels
Stricture level n
Hilar type 110
Metastasis from ovarian cancer 1
Gall bladder cancer 1
Hilar type 410
Gall bladder cancer 4
Bile duct cancer 5
Metastasis from small bowel cancer 1
Hilar metastasis of unknown origin 1
Pancreatic cancer 1
Junction between hepatic duct and common bile duct
Gall bladder cancer 1
Pancreatic cancer 1
Distal
Pancreatic cancer 39
Cystadenocarcinoma 1
Chronic pancreatitis and lung cancer 1
Duodenal cancer 1
Colon cancer metastasis 1
Cancer of the papilla of Vater 4
Small bowel cancer 1
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Bismuth–Corlette classification is shown in Fig. 1. Fifty patients
had a more distal stricture. In two cases the stricture was located at
the junction of the hepatic duct and common bile duct. In 48 cases
the stricture was located near or above the papilla of Vater.
Median overall survival was estimated to be 3.8 months; the first
quartile amounted to 1.5 months and the third quartile to 9.7
months.Six months after stent insertion,16 patients remained alive
with a patent stent. Twelve months after stent insertion, this
number had decreased to six. Stent failure was seen in 19 of 64
patients (30%), the causes of which are presented in Table 2. Only
four patients survived>30 days (range 3.7–10.0 months) after stent
failure. Failure within 30 days occurred in six patients (9%). Five
of these patients had a distal tumour and one had a hilar tumour
type 4. The diameter of the stent was 10 mm in four, and 9 mm and
8 mm in one patient each. The reason for failure within 30 days
was related to stent fracture in one case and stent occlusion in one.
Despite adequate drainage in three of the patients with both stents
and PTBD, liver function deteriorated and the subjects died. Late
stent failures (>30 days; range 1.0–21.1 months) was seen in 16
of 64 patients (25%). A pancreatic tumour treated with a stent is
shown in Fig. 2 and a hilar tumour type 4 is shown in Fig. 3.
In a Kaplan–Meier analysis in which death but patent stent was
considered a censored event, median patency was found to be
longer than overall survival (Fig. 4).
In a Kaplan–Meier analysis based on the whole sample, median
patency was estimated at 11.4 months (first quartile 3.4 months,
third quartile 16.2 months). Stent diameter >10 mm and a distal
location of the stricture were found to be associated with signifi-
cantly longer patency time in univariate analysis (Table 3). In the
multivariate analysis, only the location of the stricture was found
to be independently and significantly associated with patency
time. Kaplan–Meier curves stratified for stent diameter and type
of stricture are shown in Figs 5 and 6.
Discussion
In the present study, the median stent patency time was found to
be approximately 1 year. Given the very poor prognosis of patients
with these diagnoses, 1 year is usually sufficient. The relief
achieved by internal drainage may give patients a relatively good
quality of life for the final period of their lives, without requiring
them to rely on constant support from health care services, as is
often the case with other forms of drainage.
Figure 1 The Bismuth–Corlette classification of hilar tumours10
Table 2 Stent types and causes of failure
n %
Stent type
Wallstent™ 4 6
ZA™ 8 12
Luminexx™ 48 75
Sinus Flex™ 4 6
Causes of failure
Stent fracture 4 6
Tumour overgrowth 13 20
Clotting 1 2
Miscellaneous causes 1 2
(A) (B)
Figure 2 A 63-year-old woman diagnosed with a carcinoma of the head of the pancreas. (A) Contrast medium injection after percutaneous
transhepatic placement of a drainage catheter into the duodenum. The distal common bile duct is obstructed. (B) Six weeks later a
Luminexx(tm) stent (diameter 10 mm, length 8 cm) was placed in the common bile duct with the distal part of the stent protruding into the
duodenum
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As death with a patent stent was treated as a censored event,
median patency was found to be longer than overall survival. The
number of patients at risk for an event is therefore very low
towards the end of the period of observation. Because the chance
of being censored as a result of death with a patent stent was found
to be higher than the chance of survival with a stent that had
ceased to function, estimated projected stent patency time was
higher than overall survival.
Until recently, there has been no way of prolonging survival
for patients with tumours that most commonly cause malignant
biliary obstruction, in whom surgery is not possible. Decisions
on how to manage the obstruction have thus been based on the
assumption of a very short life expectancy. However, studies
from the last decade have shown that chemotherapy and radio-
therapy may prolong the life of patients with pancreatic cancer 2
and cholangiocarcinoma11 in selected cases. This has to be taken
into account before inserting an SEMS which may cease to func-
tion before the tumour has progressed. In such cases, surgical
biliary anastomoses, drainage by PTBD or endoscopic stenting
with plastic stents may be considered. Although plastic stents
have shorter patency time than metal stents,8,12 they can be repo-
sitioned or extracted once deployed, which is much more diffi-
cult with metal stents. However, in the event of a metal stent
ceasing to function, a new stent can be positioned within the
first.
Metal stents are more expensive than plastic stents.6 However,
the costs of health care interventions in patients with percutane-
ous biliary drainage, or the cost of a surgical biliary drainage
procedure, far outweigh the cost of the SEMS. The development of
covered stents12,13 may increase patency even more, although the
advantage in terms of prolonged patency has not yet been fully
proved.14
All patients were managed temporarily with PTBD for a period
of 1 month. This may have contributed to the long patency
observed in our study because patients with very rapidly progress-
ing tumours or poor liver function had less chance of being con-
sidered for percutaneous stenting. The vast majority of patients
with such poor prognoses died with a PTBD before being consid-
ered for percutaneous stenting.
The choice of management of patients with malignant biliary
obstruction is largely a matter of local tradition and competence.
(A) (B) (C)
Figure 3 A 71-year-old woman diagnosed with a cholangiocarcinoma. (A) Percutaneous transhepatic cholangiogram demonstrating dilated
bile ducts of the right liver lobe with a stricture at the level of the hilum and no filling of the left bile duct or common bile duct. (B) Contrast
medium injection after percutaneous transhepatic placement of drainage catheters through both the right and left liver lobes into the
duodenum, showing a stricture at the level of the hilum involving the main left and right bile ducts. (C) Contrast filling of the bile ducts after
placing Luminexx(tm) stents from the right and left sides. One of the stents protrudes into the duodenum
0
0.0
0.2
0.4
0.6
0.8
1.0
5 10 15 20
Months
25 30
P
er
ce
n
ta
g
e 
w
it
h
 p
at
en
t 
st
en
ts
Figure 4 Patency time, all patients
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Table 3 Univariate and multivariate Cox proportional hazard analyses of variables predicting stent failure
Factor Univariate model Final multivariate model
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age
median (72 years) 1 Reference
>median (72 years) 0.48 0.21–1.14 0.096
Gender
Female 1 Reference
Male 0.78 0.32–1.89 0.58
Stent diameter
median (10 mm) 1 Reference
<median (10 mm) 2.39 1.009–5.67 0.048
Stent length
<median (80 mm) 1 Reference
median (80 mm) 1.48 0.54–4.10 0.45
Proximal stent overlap
<median (20 mm) 1 Reference
median (20 mm) 0.50 0.21–1.22 0.13
Distal stent overlap
<median (20 mm) 1 Reference
median (20 mm) 1.37 0.57–3.29 0.48
Stent protruding through papilla of Vater
<median (15 mm) 1 Reference
median (15 mm) 0.67 0.26–1.71 0.40
Stricture location
Distal 1 Reference 1 Reference
Proximal 1.95 1.14–3.34 0.015 1.95 1.14–3.34 0.015
The multivariate analysis was constructed by stepwise selection, with entry testing based on the significance of the score statistic, and removal testing
based on the probability of a likelihood ratio statistic based on the maximum partial likelihood estimates. The analysis is based on the 56 patients for
whom data on all variables were available
95% CI, 95% confidence interval
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Figure 5 Kaplan–Meier curves stratified for location of the
obstruction
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Figure 6 Kaplan–Meier curves stratified for stent diameter
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Percutaneous transhepatic biliary stenting relies on the presence
of an experienced interventional radiologist and effective
co-operation between the clinician and radiologist.
Whereas relatively long patency times were seen for patients
with obstructions located distally, the outcome was much worse
for hilar tumours. The prognoses of patients with inoperable hilar
cholangiocarcinomas are often very poor, irrespective of treat-
ment.15 The shorter patency time of metal stents in patients with
hilar tumours compared with patients with distal tumours has
been observed previously 16,17 and has been attributed to tumour
overgrowth of the stent. In our study, we saw a tendency towards
reduced risk for stent failure when a proximal overlap 20 mm
was applied, although the association was not significant.
Only four of 22 patients lived >30 days after the first stent
failure. The poor survival following stent failure probably reflects
the fact that many of the failures were caused by accelerated
tumour progression. In such cases, all attempts to achieve bile
drainage become futile.
Conclusions
Percutaneous stenting is a good alternative for patients with
obstructive jaundice and a life expectancy of 1 year. It can give
instant relief from the symptoms associated with jaundice and
allow the patient to remain independent of support from health
care services during the final months of his or her life. Patency
time is, however, short for Klatskin tumours. Patency time may be
prolonged by using stents with a diameter 10 mm and placing
them with the proximal end 20 mm above the stricture.
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